Bcr-Abl
Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.
Bcr-Abl Isoform Specific Products
All Product Categories
-
Bcr-Abl Inhibitors
(200)
View all products
-
Bcr-Abl Antagonist
(1)
View all products
-
Bcr-Abl Activator
(1)
View all products
-
Bcr-Abl Modulators
(2)
View all products
-
Bcr-Abl Degraders
(24)
View all products
-
Bcr-Abl Control
(1)
View all products
-
Bcr-Abl Substrate
(1)
View all products
-
ABL1 Proteins
(6)
View all products
-
Bcr-Abl Related Products (248)
Related Products (248)
-
Recombinant Proteins (6)
-
Antibodies (6)
-
Bcr-Abl Isoform Comparison
-
Dasatinib-d4
0 ImagesCat. No.: HY-10181S1CAS No.: 1160297-08-4Synonyms: BMS-354825-d4Dasatinib-d4 (BMS-354825-d4) is deuterium labeled Dasatinib. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.
-
Cenisertib (Standard)
0 ImagesSynonyms: AS-703569 (Standard); R-763 (Standard)Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia.
-
Asciminib (Standard)
0 ImagesSynonyms: ABL001 (Standard)Asciminib (Standard) is the analytical standard of Asciminib. This product is intended for research and analytical applications. Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.
-
GZD856
0 ImagesCat. No.: HY-101489CAS No.: 1257628-64-0
-
Bosutinib-13C,d3
0 ImagesCat. No.: HY-10158S1Synonyms: SKI-606-13C,d3Bosutinib-13C,d3 (SKI-606-13C,d3) is 13C labeled Bosutinib. Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
-
BCR-ABL-IN-3
0 ImagesCat. No.: HY-136526CAS No.: 2240191-12-0
-
CHMFL-ABL-121
0 ImagesCat. No.: HY-119370CAS No.: 2270879-07-5CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively.
-
CHMFL-ABL/KIT-155
0 ImagesCat. No.: HY-101034CAS No.: 2081093-21-0Synonyms: CHMFL-ABL-KIT-155CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis.
-
SNIPER(ABL)-033
0 ImagesCat. No.: HY-111871CAS No.: 2222354-18-7SNIPER(ABL)-033, conjugating HG-7-85-01 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM (ABL inhibitor: HY-15814; ABL inhibitor activity control: HY-131178; E3 ligase ligand: HY-128808; linker: HY-130500; E3 ligase ligand + linker: HY-128819).
-
CT-721
0 ImagesCat. No.: HY-108704CAS No.: 1388710-60-8CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities. CT-721 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
AZD0424
0 ImagesCat. No.: HY-112314CAS No.: 692054-06-1AZD0424 is an orally active, and dual selective Src/Abl kinase inhibitor with potential antineoplastic activity. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells.
-
SNIPER(ABL)-050
0 ImagesCat. No.: HY-111858SNIPER(ABL)-050, conjugating Imatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.
-
SNIPER(ABL)-024
0 ImagesCat. No.: HY-111861CAS No.: 2222355-77-1SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 5μM.
-
AT9283 lactic acid
0 ImagesCat. No.: HY-10058CAS No.: 896466-76-5AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo.
-
SNIPER(ABL)-044
0 ImagesCat. No.: HY-111862SNIPER(ABL)-044, conjugating HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 μM.
-
SNIPER(ABL)-013
0 ImagesCat. No.: HY-111860SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 20 μM.
-
SNIPER(ABL)-019
0 ImagesCat. No.: HY-111873SNIPER(ABL)-019, conjugating Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 0.3 μM.
-
Relcobatinib
0 ImagesCat. No.: HY-184100SCAS No.: 2767305-95-1Synonyms: RelcobatinibumRelcobatinib (Relcobatinibum) is a ABL1 kinase inhibitor with an IC50 of 12.7 nM against wild-type ABL1 and an IC50 of 43.5 nM against the ABL1T315I mutant. Relcobatinib inhibits the phosphorylation of CRKL. Relcobatinib exhibits anticancer activity against chronic myeloid leukemia. Relcobatinib can be used in studies related to chronic myeloid leukemia.
-
SNIPER(ABL)-058
0 ImagesCat. No.: HY-111859CAS No.: 2222354-61-0SNIPER(ABL)-058, conjugating Imatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 μM.
